Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages

Key Points

• Analyst consensus: Thirteen brokerages give Taysha Gene Therapies an average rating of "Buy" (10 buys, 2 strong buys, 1 sell) with an average 1‑year price target of about $11.64, well above the current share price.
• Insider selling notable: Insiders sold 598,623 shares worth $2.77M in the last three months (including CEO Sean Nolan and Sukumar Nagendran), leaving insiders with 3.78% ownership while institutions hold 77.7%.
• Operational update: The company is a clinical‑stage gene therapy developer with lead programs for GM2, GM1 and AADC disorders, and it recently beat quarterly estimates with EPS of ($0.08) vs. ($0.11) expected and revenue of $5.49M vs. $1.89M expected.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has received an average rating of "Buy" from the thirteen brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $11.6364.

A number of brokerages have commented on TSHA. Truist Financial raised Taysha Gene Therapies to a "strong-buy" rating in a report on Wednesday, March 25th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Wall Street Zen raised Taysha Gene Therapies from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, April 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Taysha Gene Therapies in a report on Friday, March 27th.

Insider Transactions at Taysha Gene Therapies

In other news, CEO Sean P. Nolan sold 41,312 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the sale, the chief executive officer directly owned 2,908,257 shares of the company's stock, valued at approximately $13,407,064.77. This represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 598,623 shares of company stock valued at $2,772,188. 3.78% of the stock is owned by corporate insiders.

Institutional Trading of Taysha Gene Therapies

Several large investors have recently modified their holdings of the stock. Intech Investment Management LLC grew its holdings in shares of Taysha Gene Therapies by 3.6% during the 4th quarter. Intech Investment Management LLC now owns 71,069 shares of the company's stock worth $391,000 after purchasing an additional 2,443 shares in the last quarter. Chicago Partners Investment Group LLC grew its holdings in shares of Taysha Gene Therapies by 1.5% during the 4th quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company's stock worth $916,000 after purchasing an additional 2,504 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Taysha Gene Therapies by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company's stock worth $73,000 after buying an additional 2,765 shares during the last quarter. Virtus Investment Advisers LLC lifted its position in shares of Taysha Gene Therapies by 7.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company's stock worth $253,000 after buying an additional 3,008 shares during the last quarter. Finally, Xponance Inc. lifted its position in shares of Taysha Gene Therapies by 29.1% during the 3rd quarter. Xponance Inc. now owns 16,575 shares of the company's stock worth $54,000 after buying an additional 3,738 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $4.71 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. The stock's fifty day moving average price is $4.53 and its two-hundred day moving average price is $4.73. Taysha Gene Therapies has a one year low of $1.13 and a one year high of $6.02. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -13.85 and a beta of 1.10.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to analyst estimates of $1.89 million. On average, equities analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.